Header Logo

Connection

ANNE TSAO to Humans

Back to Details
This is a "connection" page, showing publications ANNE TSAO has written about Humans.
ANNE TSAO
Connection Strength
0.679
Humans
  1. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol. 2022 02 20; 40(6):681-692.
    View in: PubMed
    Score: 0.016
  2. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
    View in: PubMed
    Score: 0.014
  3. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
    View in: PubMed
    Score: 0.013
  4. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547.
    View in: PubMed
    Score: 0.013
  5. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Semin Oncol. 2019 04; 46(2):145-154.
    View in: PubMed
    Score: 0.013
  6. Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:553-562.
    View in: PubMed
    Score: 0.013
  7. Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol. 2019 02 14; 20(2):18.
    View in: PubMed
    Score: 0.013
  8. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.012
  9. Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. J Thorac Oncol. 2018 07; 13(7):871-873.
    View in: PubMed
    Score: 0.012
  10. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 02; 13(2):246-257.
    View in: PubMed
    Score: 0.012
  11. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308.
    View in: PubMed
    Score: 0.011
  12. Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. J Oncol Pract. 2017 01; 13(1):e62-e67.
    View in: PubMed
    Score: 0.011
  13. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.
    View in: PubMed
    Score: 0.010
  14. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2016 Mar; 17(2):e5-11.
    View in: PubMed
    Score: 0.010
  15. Current readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg. 2014; 26(4):323-30.
    View in: PubMed
    Score: 0.010
  16. Local and systemic therapies for malignant pleural mesothelioma. Curr Treat Options Oncol. 2014 Dec; 15(4):683-99.
    View in: PubMed
    Score: 0.010
  17. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
    View in: PubMed
    Score: 0.009
  18. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.
    View in: PubMed
    Score: 0.009
  19. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
    View in: PubMed
    Score: 0.009
  20. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Med. 2013 Jun; 2(3):351-9.
    View in: PubMed
    Score: 0.008
  21. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21.
    View in: PubMed
    Score: 0.008
  22. Mesothelioma. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S399-400.
    View in: PubMed
    Score: 0.008
  23. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.008
  24. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.008
  25. Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1789-90.
    View in: PubMed
    Score: 0.008
  26. Mesothelioma and small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1825-6.
    View in: PubMed
    Score: 0.008
  27. The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614.
    View in: PubMed
    Score: 0.007
  28. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74.
    View in: PubMed
    Score: 0.007
  29. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar; 6(3):598-601.
    View in: PubMed
    Score: 0.007
  30. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer. 2010 Nov 01; 11(6):371-3.
    View in: PubMed
    Score: 0.007
  31. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010 Jun 29; 2:15.
    View in: PubMed
    Score: 0.007
  32. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
    View in: PubMed
    Score: 0.007
  33. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90.
    View in: PubMed
    Score: 0.006
  34. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jan; 10(1):36-41.
    View in: PubMed
    Score: 0.006
  35. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.
    View in: PubMed
    Score: 0.006
  36. Eighth international mesothelioma interest group. Oncogene. 2007 Oct 25; 26(49):6959-67.
    View in: PubMed
    Score: 0.006
  37. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.005
  38. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006 Jun 01; 106(11):2428-36.
    View in: PubMed
    Score: 0.005
  39. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9.
    View in: PubMed
    Score: 0.005
  40. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
    View in: PubMed
    Score: 0.005
  41. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.005
  42. The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer. Cancer. 2024 Dec 15; 130(24):4200-4212.
    View in: PubMed
    Score: 0.005
  43. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. 2024 Oct; 19(10):1438-1448.
    View in: PubMed
    Score: 0.005
  44. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer. 2004 May 15; 100(10):2240-5.
    View in: PubMed
    Score: 0.005
  45. Chemoprevention of cancer. CA Cancer J Clin. 2004 May-Jun; 54(3):150-80.
    View in: PubMed
    Score: 0.005
  46. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 01; 10(4):475-483.
    View in: PubMed
    Score: 0.005
  47. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8.
    View in: PubMed
    Score: 0.005
  48. Navigating professionalism challenges: Impact on patient safety. J Clin Anesth. 2024 08; 95:111427.
    View in: PubMed
    Score: 0.005
  49. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer. Future Oncol. 2024; 20(16):1047-1055.
    View in: PubMed
    Score: 0.005
  50. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 01; 98(11):2483-7.
    View in: PubMed
    Score: 0.004
  51. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506.
    View in: PubMed
    Score: 0.004
  52. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.004
  53. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):660-4.
    View in: PubMed
    Score: 0.004
  54. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 07 20; 41(21):3700-3711.
    View in: PubMed
    Score: 0.004
  55. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.004
  56. Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. J Thorac Cardiovasc Surg. 2023 08; 166(2):362-371.e9.
    View in: PubMed
    Score: 0.004
  57. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117.
    View in: PubMed
    Score: 0.004
  58. STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002 Oct; 119(1):15-24.
    View in: PubMed
    Score: 0.004
  59. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol. 2022 10; 23(10):1321-1331.
    View in: PubMed
    Score: 0.004
  60. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.
    View in: PubMed
    Score: 0.004
  61. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.
    View in: PubMed
    Score: 0.004
  62. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022 05; 167:8-16.
    View in: PubMed
    Score: 0.004
  63. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022 05; 33(5):488-499.
    View in: PubMed
    Score: 0.004
  64. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.004
  65. Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small?cell lung cancer: phase II PHAROS study design. Future Oncol. 2022 Mar; 18(7):781-791.
    View in: PubMed
    Score: 0.004
  66. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.004
  67. Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med. 2022 Aug; 37(8):1055-1059.
    View in: PubMed
    Score: 0.004
  68. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.
    View in: PubMed
    Score: 0.004
  69. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5.
    View in: PubMed
    Score: 0.004
  70. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.004
  71. Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 01; 113(1):200-208.
    View in: PubMed
    Score: 0.004
  72. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 07; 11(7):1688-1699.
    View in: PubMed
    Score: 0.004
  73. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep. 2021 02 25; 11(1):4530.
    View in: PubMed
    Score: 0.004
  74. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.004
  75. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 01 30; 397(10272):375-386.
    View in: PubMed
    Score: 0.004
  76. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277.
    View in: PubMed
    Score: 0.004
  77. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2021 Feb; 76(2):155.e25-155.e34.
    View in: PubMed
    Score: 0.004
  78. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist. 2020 11; 25(11):e1794-e1802.
    View in: PubMed
    Score: 0.004
  79. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.
    View in: PubMed
    Score: 0.004
  80. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 05; 22(3):e451-e465.
    View in: PubMed
    Score: 0.003
  81. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.003
  82. Reply to Waller et?al. Standardizing Surgical Treatment for Mesothelioma. J Thorac Oncol. 2020 05; 15(5):e75-e77.
    View in: PubMed
    Score: 0.003
  83. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.003
  84. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12.
    View in: PubMed
    Score: 0.003
  85. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.003
  86. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer. 2020 02; 1(2):176-183.
    View in: PubMed
    Score: 0.003
  87. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.003
  88. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 09; 69(5):402-429.
    View in: PubMed
    Score: 0.003
  89. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.
    View in: PubMed
    Score: 0.003
  90. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol. 2019 08; 14(8):1343-1353.
    View in: PubMed
    Score: 0.003
  91. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019 07; 14(7):1172-1183.
    View in: PubMed
    Score: 0.003
  92. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019 07; 7(7):569-580.
    View in: PubMed
    Score: 0.003
  93. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.003
  94. Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2019 09; 158(3):924-929.
    View in: PubMed
    Score: 0.003
  95. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
    View in: PubMed
    Score: 0.003
  96. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol. 2018 09; 13(9):1269-1283.
    View in: PubMed
    Score: 0.003
  97. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.
    View in: PubMed
    Score: 0.003
  98. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
    View in: PubMed
    Score: 0.003
  99. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265.
    View in: PubMed
    Score: 0.003
  100. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018 02 12; 33(2):244-258.e10.
    View in: PubMed
    Score: 0.003
  101. Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist. 2018 05; 23(5):526-e49.
    View in: PubMed
    Score: 0.003
  102. Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners. J Pain Symptom Manage. 2018 03; 55(3):953-961.
    View in: PubMed
    Score: 0.003
  103. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.
    View in: PubMed
    Score: 0.003
  104. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2017 Dec 15; 23(24):7483-7489.
    View in: PubMed
    Score: 0.003
  105. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.
    View in: PubMed
    Score: 0.003
  106. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer. 2017 10; 112:181-187.
    View in: PubMed
    Score: 0.003
  107. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.
    View in: PubMed
    Score: 0.003
  108. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209.
    View in: PubMed
    Score: 0.003
  109. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clin Lung Cancer. 2017 09; 18(5):589-593.
    View in: PubMed
    Score: 0.003
  110. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.003
  111. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 08; 11(8):1246-1262.
    View in: PubMed
    Score: 0.003
  112. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016 08 10; 34(23):2761-8.
    View in: PubMed
    Score: 0.003
  113. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage. 2016 07; 52(1):8-16.e1.
    View in: PubMed
    Score: 0.003
  114. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
    View in: PubMed
    Score: 0.002
  115. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91.
    View in: PubMed
    Score: 0.002
  116. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56.
    View in: PubMed
    Score: 0.002
  117. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol. 2014 Jul; 9(7):998-1007.
    View in: PubMed
    Score: 0.002
  118. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004 Jun 01; 100(11):2486-7; author reply 2487-8.
    View in: PubMed
    Score: 0.002
  119. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.
    View in: PubMed
    Score: 0.002
  120. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
    View in: PubMed
    Score: 0.002
  121. Recurrence of malignant pleural mesothelioma at the resection borders--local or distant recurrence? J Thorac Oncol. 2013 Jul; 8(7):e65-6.
    View in: PubMed
    Score: 0.002
  122. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.002
  123. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
    View in: PubMed
    Score: 0.002
  124. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20.
    View in: PubMed
    Score: 0.002
  125. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.002
  126. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
    View in: PubMed
    Score: 0.002
  127. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45.
    View in: PubMed
    Score: 0.002
  128. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.002
  129. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13.
    View in: PubMed
    Score: 0.002
  130. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.
    View in: PubMed
    Score: 0.002
  131. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010 Sep; 69(3):337-40.
    View in: PubMed
    Score: 0.002
  132. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct 24; 8:91.
    View in: PubMed
    Score: 0.002
  133. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):326-37.
    View in: PubMed
    Score: 0.002
  134. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. 2009 Jun; 4(6):689-96.
    View in: PubMed
    Score: 0.002
  135. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20; 26(9):1472-8.
    View in: PubMed
    Score: 0.001
  136. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3.
    View in: PubMed
    Score: 0.001
  137. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.001
  138. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3.
    View in: PubMed
    Score: 0.001
  139. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.
    View in: PubMed
    Score: 0.001
  140. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg. 2003 Oct; 15(4):405-20.
    View in: PubMed
    Score: 0.001
  141. Comparison of alveolar bone loss, alveolar bone density and second metacarpal bone density, salivary and gingival crevicular fluid interleukin-6 concentrations in healthy premenopausal and postmenopausal women on estrogen therapy. J Gerontol A Biol Sci Med Sci. 1997 Nov; 52(6):M343-51.
    View in: PubMed
    Score: 0.001
  142. Interaction of cells with UHMWPE impregnated with the bioactive peptides RGD, RGE or Poly-L-lysine. Biomed Sci Instrum. 1997; 34:41-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.